Crystalys Therapeutics
Focus: Crystalys is a Series A biotech focused on oral URAT1 inhibitors for gout, a large metabolic disease market with significant unmet need. The company is pre-revenue and early-stage, based in San Diego's biotech hub.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
0
About Crystalys Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Crystalys Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Growth
Phase 3 program targeting improved oral bioavailability of a standard-of-care gout therapy with significant patient demand.
Products & Portfolio (1)
Help build intelligence for Crystalys Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.